Literature DB >> 12917925

Methadone maintenance at different dosages for opioid dependence.

F Faggiano1, F Vigna-Taglianti, E Versino, P Lemma.   

Abstract

BACKGROUND: Methadone maintenance treatment (MMT) is a long term opioid replacement therapy, recognised as effective in the management of opioid dependence. Even if MMT at high dosage is recommended as therapy for reducing illicit opioid use and promoting longer retention in treatment, at present day "the organisation and regulation of the methadone maintenance treatment varies widely".
OBJECTIVES: To evaluate the efficacy of different dosages of MMT for opioid dependence in modifying health and social outcomes and in promoting patients' familial, occupational and relational functioning. SEARCH STRATEGY: The following sources were scanned: - MEDLINE (OVID 1966-2001)- EMBASE (1988-2001)- ERIC (1988-2001)- Psychinfo (1947-2001)- Cochrane Controlled Trials Register (CCTR) (1947-2001)- Register of the Cochrane Drug and Alcohol Group (CDAG) (1947-2001)The CDAG search strategy was applied together with a specific MESH strategy. Further studies were searched through: letters to the authors of selected trials or to experts in order to obtain unpublished data. check of references of relevant reviews. SELECTION CRITERIA: Randomised Controlled Trials (RCT) and Controlled Prospective Studies (CPS) evaluating methadone maintenance at different dosages in the management of opioid dependence were included in the review. Non-randomised trials were included when proper adjustment for confounding factors was performed at the analysis stage. DATA COLLECTION AND ANALYSIS: Extraction of data was performed separately by two reviewers. Discrepancies were resolved by a third reviewer. RevMan software was used for analysis. Quality assessments of the methodology of studies were carried out using CDAG checklist. MAIN
RESULTS: 22 studies were excluded from the review. 21 studies were included; of them, 11 were RCTs with 2279 people randomised and 10 were CPSs with 3715 people followed-up. OUTCOMES: Retention rate - RCTs: High vs low doses at shorter follow-ups: RR=1.36 [1.13,1.63], and at longer ones: RR=1.62 [0.95,2.77]. Opioid use (self reported), times/w - RCTs: high vs low doses WMD= -2.00 [-4.77,0.77] high vs middle doses WMD= -1.89[-3.43, -0.35] Opioid abstinence, (urine based) at >3-4 w - RCTs: high vs low ones: RR=1.59 [1.16,2.18] high vs middle doses RR=1.51[0.63,3.61] Cocaine abstinence (urine based) at >3-4 w - RCTs: high vs low doses RR=1.81 [1.15,2.85]Overdose mortality - CPSs: high dose vs low dose at 6 years follow up: RR=0.29 [0.02-5.34] high dose vs middle dose at 6 years follow up: RR=0.38 [0.02-9.34] middle dose vs low dose at 6 years follow up: RR=0.57 [0.06-5.06] REVIEWER'S
CONCLUSIONS: Methadone dosages ranging from 60 to 100 mg/day are more effective than lower dosages in retaining patients and in reducing use of heroin and cocaine during treatment. To find the optimal dose is a clinical ability, but clinician must consider these conclusions in treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917925     DOI: 10.1002/14651858.CD002208

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  102 in total

1.  Methadone dose, take home status, and hospital admission among methadone maintenance patients.

Authors:  Alexander Y Walley; Debbie M Cheng; Courtney E Pierce; Clara Chen; Tiffany Filippell; Jeffrey H Samet; Daniel P Alford
Journal:  J Addict Med       Date:  2012-09       Impact factor: 3.702

2.  [Maintenance treatment in opioid-dependent patients with migration background].

Authors:  L K Bald; M Schouler-Ocak; S Penka; N Schoofs; T Häbel; F Bermpohl; S Gutwinski
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

Review 3.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 4.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

Review 5.  Methadone tolerance testing in drug misusers.

Authors:  Adam Bakker; Cindy Fazey
Journal:  BMJ       Date:  2006-11-18

Review 6.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

Review 7.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

8.  A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.

Authors:  Ned J Presnall; D A Patterson Silver Wolf; Derek S Brown; Sara Beeler-Stinn; Richard A Grucza
Journal:  J Subst Abuse Treat       Date:  2019-06-15

9.  Correlates of methadone client retention: a prospective cohort study in Guizhou province, China.

Authors:  Enwu Liu; Tao Liang; Limei Shen; Huan Zhong; Bing Wang; Zunyou Wu; Roger Detels
Journal:  Int J Drug Policy       Date:  2008-10-31

Review 10.  Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.

Authors:  Margaret Haney
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.